Associate Director of Strategic Initiatives – Roger Stupp, MD
An internationally recognized authority on the treatment of primary and metastatic brain cancer, Roger Stupp, MD, is chief of Neuro-Oncology in the Department of Neurology at Northwestern University Feinberg School of Medicine and Co-Director of the Northwestern Medicine Lou and Jean Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University at Northwestern Memorial Hospital. As director of Strategic Initiatives, he is instrumental in the development and oversight of Lurie Cancer Center’s strategic scientific initiatives applying advanced technologies and collaborative approaches to accelerate and widen the scope of clinical research.
In 2005, Dr. Stupp led clinical research demonstrating that chemotherapy with the drug temozolomide in conjunction with radiotherapy increases survival for patients with glioblastoma, the most common type of malignant brain tumor in adults. Later, Stupp and colleagues showed that electromagnetic waves called tumor treating fields can substantially improve outcomes for patients suffering from glioblastoma. These breakthrough discoveries led to the last two FDA-approved treatments for the disease.
His current research focus includes the multimodality management of primary and secondary brain tumors, head and neck tumors, and lung cancers, as well as new drug development and the association of chemotherapy and radiation therapy. Dr. Stupp also serves as president of the European Organization for Research and Treatment of Cancer and section editor of the European Journal of Cancer. Among many honors and awards recognizing his contributions to cancer science, he received the European Society for Medical Oncology’s Hamilton Fairley Award and the Society for NeuroOncology’s Victor Levin Award. Dr. Stupp has published more than 200 peer-reviewed journal articles, editorials and book chapters.Back to top